These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6511863)

  • 1. Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent.
    Matlis R; Greenblatt DJ
    J Chromatogr; 1984 Oct; 310(2):445-9. PubMed ID: 6511863
    [No Abstract]   [Full Text] [Related]  

  • 2. Macro- and micromethods for high-performance liquid chromatographic analysis of oxaprozin in plasma.
    McHugh SL; Kirkman SK; Knowles JA
    J Pharm Sci; 1980 Jul; 69(7):794-6. PubMed ID: 7391941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein binding and clearance of oxaprozin, a highly bound anti-inflammatory agent.
    Homon CA; Fluck ER; Janssen FW; Ruelius HW
    Agents Actions; 1982 Apr; 12(1-2):211-5. PubMed ID: 7080958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application].
    Mao M; Wang L; Jiang X; Yang L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Jun; 30(3):646-50. PubMed ID: 23865335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaprozin dose proportionality.
    Chiang ST; Lasseter KC; Fluck ER; Janssen FW; Leelavathi D; Hubsher JA
    J Clin Pharmacol; 1984; 24(11-12):515-22. PubMed ID: 6511991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-inflammatory activity of a non-steroidal anti-inflammatory agent, oxaprozin, in experimental models].
    Higuchi S; Osada Y; Shioiri Y; Nakaike S; Muramatsu M; Tanaka M; Arai I; Amanuma F; Otomo S; Aihara H
    Nihon Yakurigaku Zasshi; 1984 May; 83(5):383-94. PubMed ID: 6432656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaprozin pharmacokinetics in the elderly.
    Greenblatt DJ; Matlis R; Scavone JM; Blyden GT; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1985 Mar; 19(3):373-8. PubMed ID: 3986088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatography assay for fenbufen and two serum metabolites.
    Fleitman JS; Schulman SG; Perrin JH
    J Chromatogr; 1982 Mar; 228():372-6. PubMed ID: 7076764
    [No Abstract]   [Full Text] [Related]  

  • 9. [The analgesic and antipyretic effects of a non-steroidal anti-inflammatory drug, oxaprozin, in experimental animals].
    Amanuma F; Okuyama S; Orikasa S; Hashimoto S; Yamada C; Sakagawa T; Tsutsui Y; Tarumoto Y; Aihara H; Kameyama T
    Nihon Yakurigaku Zasshi; 1984 Apr; 83(4):345-54. PubMed ID: 6611288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose.
    Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J
    J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of food on oxaprozin bioavailability.
    Chiang ST; Knowles JA; Hubsher JA; Ruelius HW; Walker BR
    J Clin Pharmacol; 1984; 24(8-9):381-5. PubMed ID: 6480879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of co-administered drugs on oxaprozin binding to human serum albumin.
    Aubry AF; Markoglou N; Adams MH; Longstreth J; Wainer IW
    J Pharm Pharmacol; 1995 Nov; 47(11):937-44. PubMed ID: 8708989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Todd PA; Brogden RN
    Drugs; 1986 Oct; 32(4):291-312. PubMed ID: 3536423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and kinetics of oxaprozin in normal subjects.
    Janssen FW; Jusko WJ; Chiang ST; Kirkman SK; Southgate PJ; Coleman AJ; Ruelius HW
    Clin Pharmacol Ther; 1980 Mar; 27(3):352-62. PubMed ID: 7357792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.
    Audet PR; Knowles JA; Troy SM; Walker BR; Morrison G
    Clin Pharmacol Ther; 1988 Sep; 44(3):303-9. PubMed ID: 3416552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The inhibitory effect of oxaprozin, a new non-steroidal anti-inflammatory drug, on platelet aggregation].
    Goto J; Muramatsu M; Hosoda K; Otomo S; Aihara H
    Nihon Yakurigaku Zasshi; 1984 May; 83(5):395-400. PubMed ID: 6432657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between oxaprozin glucuronide and human serum albumin.
    Wells DS; Janssen FW; Ruelius HW
    Xenobiotica; 1987 Dec; 17(12):1437-49. PubMed ID: 3439193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaprozin prodrug as safer nonsteroidal anti-inflammatory drug: Synthesis and pharmacological evaluation.
    Peesa JP; Atmakuri LR; Yalavarthi PR; Mandava Venkata BR; Rasheed A; Pachava V
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29283449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uricosuric effect of oxaprozin in humans.
    Goldfarb S; Walker BR; Agus ZS
    J Clin Pharmacol; 1985 Mar; 25(2):144-8. PubMed ID: 3886710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaprozin disposition in renal disease.
    Chiang ST; Morrison G; Knowles JA; Ruelius HW; Walker BR
    Clin Pharmacol Ther; 1982 Apr; 31(4):509-15. PubMed ID: 7060332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.